Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials

AIMS: This analysis assessed the efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in patients with or without metabolic syndrome (MetS) using pooled data from 10 phase 3 ODYSSEY trials. MATERIALS AND METHODS: Data from 4983 randomized patients (1940 with...

Descripción completa

Detalles Bibliográficos
Autores principales: Henry, Robert R., Müller‐Wieland, Dirk, Taub, Pam R., Bujas‐Bobanovic, Maja, Louie, Michael J., Letierce, Alexia, Ginsberg, Henry N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033097/
https://www.ncbi.nlm.nih.gov/pubmed/29493859
http://dx.doi.org/10.1111/dom.13273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033097/
https://www.ncbi.nlm.nih.gov/pubmed/29493859
http://dx.doi.org/10.1111/dom.13273

Ejemplares similares